Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome. 

Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population.

This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks to head to the clinic with its acne vulgaris treatment. 

00:53-02:42: About Eligo Bioscience
 02:42-06:07: How are you creating a new class of transformative genetic medicine?
 06:08-10:07: How important is the microbiome?
 10:07-11:48: How do you account for differences in the microbiome?
 11:48-13:17: What conditions are you looking to treat?
 13:17-18:42: What is your EB005 platform?
 18:42-21:28: How will your acne treatment be administered?
 21:28-22:06: How will Eligo keep the cost of the acne treatment low?
 22:06-24:36: Will your platform be applicable to other diseases?
 24:36-25:52: Will a combination of treatments of the microbiome make a difference?
 25:52-28:14: What will the recent funding mean to Eligo Bioscience?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter